Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application

by Xiaoping Yang, Thomas W. Flaig
Published 2010-06-01

Redefining Hormone Sensitive Disease in Advanced Prostate Cancer

by Xiaoyu Hou, Thomas W. Flaig
Published 2012-01-01

Renal cell carcinoma: a review of biology and pathophysiology [version 1; referees: 2 approved]

by Shahzaib Nabi, Elizabeth R. Kessler, Brandon Bernard, Thomas W. Flaig, Elaine T. Lam
Published 2018-03-01

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer

by Steven K. Nordeen, Lih-Jen Su, Gregory A. Osborne, Perry M. Hayman, David J. Orlicky, Veronica M. Wessells, Adrie van Bokhoven, Thomas W. Flaig
Published 2021-08-01

Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia.

by Xiaoping Yang, Francisco G La Rosa, Elizabeth Erin Genova, Kendra Huber, Jerome Schaack, James Degregori, Natalie J Serkova, Yuan Li, Lih-Jen Su, Elizabeth Kessler, Thomas W Flaig
Published 2013-01-01